Arcturus outlines 12-week Phase II CF trial launch and expects regulatory clarity for ARCT-810 in 2026
Source: SeekingAlpha
2026-03-03 23:15:09 ET
More on Arcturus Therapeutics
- Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2025 Earnings Call Transcript
- Arcturus Therapeutics: Two Catalysts, One Runway, And A Stock Priced For Failure
- Seeking Alpha’s Quant Rating on Arcturus Therapeutics
- Historical earnings data for Arcturus Therapeutics
- Financial information for Arcturus Therapeutics
Read the full article on Seeking Alpha
For further details see:
Arcturus outlines 12-week Phase II CF trial launch and expects regulatory clarity for ARCT-810 in 2026
Arcturus Therapeutics Ltd.
NASDAQ: ARCT
ARCT Trading
1.9% G/L:
$7.235 Last:
254,611 Volume:
$6.89 Open:
ARCT Latest News
March 03, 2026 04:01:00 pm
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline Progress
ARCT Stock Data
$215,096,092
23,697,509
N/A
34
N/A
Biotechnology & Life Sciences
Healthcare
US
San Diego
